Impact of GLP-1 and dual agonists on the incidence of new cases of physician-reported sleep apnea: a real-world study - PubMed
6 hours ago
- #GLP-1 agonists
- #sleep apnea
- #real-world evidence
- GLP-1 and dual agonists (like tirzepatide) reduce the incidence of new physician-reported sleep apnea (PRSA) by 54% compared to non-users, based on a real-world study.
- The study included over 1.25 million matched patients with obesity and/or type 2 diabetes, followed for 1044 days, using data from the TriNetX Global Health Research Network.
- Individual drugs also showed lower PRSA incidence: liraglutide (HR 0.64), dulaglutide (HR 0.32), semaglutide (HR 0.57), and tirzepatide (HR 0.74) all had significant reductions versus controls.
- Exploratory analysis found a 79% lower incidence of positive airway pressure reports in the GLP-1/dual agonist group, suggesting reduced need for sleep apnea treatment.
- The research highlights the potential of these medications to prevent new cases of sleep apnea in high-risk populations, beyond just treating severity.